The DOI matches its Crossref record.
Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Harbeck, N., & Gnant, M. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31891-8 · Cited by 2,280
Self-citationLoibl, S., & Gianni, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32417-5 · Cited by 1,116
Self-citationTargeted therapeutic options and future perspectives for HER2-positive breast cancer
Wang, J., & Xu, B. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0069-2 · Cited by 393
Rexer, B. N., & Arteaga, C. L. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.20 · Cited by 370
Treatment of HER2-positive breast cancer
Figueroa-Magalhães, M. C., Jelovac, D., Connolly, R. M., & Wolff, A. C. (2014) · The Breast · doi:10.1016/j.breast.2013.11.011 · Cited by 273
Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer
Tang, Y., Wang, Y., Kiani, M. F., & Wang, B. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.05.012 · Cited by 265
Pivot, X., Manikhas, A., Żurawski, B., Chmielowska, E., Karaszewska, B., Allerton, R., Chan, S., Fabi, A., Bidoli, P., Gori, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1794 · Cited by 242
Lapatinib for Advanced or Metastatic Breast Cancer
Opdam, F. L., Guchelaar, H.-J., Beijnen, J. H., & Schellens, J. H. M. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0461 · Cited by 113
Bledsoe, M. J., & Grizzle, W. E. (2013) · Diagnostic Histopathology · doi:10.1016/j.mpdhp.2013.06.015 · Cited by 39
Metadata
- Authors
- von Minckwitz, G., Schwedler, K., Schmidt, M., Barinoff, J., Mundhenke, C., Cufer, T., Maartense, E., de Jongh, F. E., Baumann, K. H., Bischoff, J., Harbeck, N., Lück, H.-J., Maass, N., Zielinski, C., Andersson, M., Stein, R. C., Nekljudova, V., & Loibl, S.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2011-10
- Volume
- 47
- Issue
- 15
- Pages
- 2273-2281
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W1981701117
- Cited by
- 181
- References
- 0
- FWCI
- 8.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.